-- Recce Pharmaceuticals（ASX：RCE）周二向澳大利亚证券交易所提交的文件显示，印尼国家药品和食品控制局已完成对其在印尼开展的三期临床试验的全面例行监管检查，未发现任何妨碍该研究继续进行的问题。 这项用于治疗糖尿病足感染的三期临床试验正在推进患者给药，并有望按计划公布155名患者的中期数据。 该公司股价周二上涨2%。
Related Articles
Asia
Origin Energy Reports Lower March Quarter Production
Origin Energy (ASX:ORG) reported March quarter production of 164.5 petajoules, down from 167.1 petajoules a year earlier, according to a Monday filing with the Australian bourse.The company reported commodity revenue of AU$1.86 billion for the quarter, down from AU$ 2.31 billion a year ago, per the filing.Origin Energy also said its electricity sales volume increased 4% from a year earlier amid "strong growth" in business volumes driven largely by the data-center sector.
$ASX:ORG
Asia
New Hope Says JPMorgan Chase Ceases to be a Substantial Shareholder
New Hope (ASX:NHC) received notice that JPMorgan Chase and its affiliates are no longer substantial holders of the company from April 22, according to a Monday filing with the Australian bourse.JPMorgan Chase and its affiliates became a substantial holder of the company on April 15, with a total voting power of 5.88%, an earlier filing showed.
$ASX:NHC
Asia
Zip Says JPMorgan Chase Increases Stake
Zip (ASX:ZIP) received notice that JPMorgan Chase and its affiliates increased their holdings in the company to 7.42% from 6.27%, according to a Monday Australian bourse filing.JPMorgan Chase and its affiliates now own 93.2 million shares in the company, the filing said.
$ASX:ZIP